Render Target: STATIC
Render Timestamp: 2025-01-02T12:23:22.246Z
Commit: 286c369131ceeedcf44c821941824d8d7e009e57
XML generation date: 2024-09-20 06:23:30.841
Product last modified at: 2025-01-01T09:04:39.992Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

Salermide #31699

    Product Information

    Product Usage Information

    Salermide is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 0.84 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 394.5 g/mol
    Purity >98%
    Molecular Formula C26H22N2O2
    CAS 1105698-15-4
    Solubility Soluble in DMSO at 40 mg/mL, ethanol at 10 mg/mL, or DMF at 30 mg/mL.

    Background

    The reverse amide Salermide is a strong inhibitor of the sirtuin proteins SirT1 and SirT2. Sirtuins are nicotinamide adenine dinucleotide-dependent protein deacetylases involved in cell aging and lifespan regulation. Nuclear SirT1 is implicated in regulating apoptosis, cellular senescence, aging, and longevity; SirT2 is involved in cytoskeletal regulation and progression through mitosis. Exposure of human cancer cell lines to Salermide results in the reactivation of proapoptotic genes repressed by SirT1 and tumor-specific cell death (1). Salermide treatment of human breast cancer cells leads to decreased SirT1 expression and increased acetylation and activation of p53 (2). Inhibition of both SirT1 and SirT2 by Salermide is required to induce p53 acetylation and cell death (3). Salermide treatment of human pancreatic cancer cells potentiates the anticancer effects of a cytotoxin, reducing pancreatic cancer cell progression and stopping the cell cycle at G1 (4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.